RVL Pharmaceuticals plc (RVLP) Misses Q4 EPS by 1c

RVL Pharmaceuticals plc (NASDAQ: RVLP) reported Q4 EPS of ($0.18), $0.01 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $9.81 million versus the consensus estimate of $12.58 million.

For earnings history and earnings-related data on RVL Pharmaceuticals plc (RVLP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Reading (RDI) Tops Q2 EPS by 4c